163 related articles for article (PubMed ID: 32160976)
1. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib.
Chen G; Hu K; Sun H; Zhou J; Song D; Xu Z; Gao L; Lu Y; Cheng Y; Feng Q; Zhang H; Wang Y; Hu L; Lu K; Wu X; Li B; Zhu W; Shi J
Cancer Lett; 2020 May; 478():45-55. PubMed ID: 32160976
[TBL] [Abstract][Full Text] [Related]
2. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.
Gao M; Li B; Sun X; Zhou Y; Wang Y; Tompkins VS; Xu Z; Indima N; Wang H; Xiao W; Gao L; Chen G; Wu H; Wu X; Kong Y; Xie B; Zhang Y; Chang G; Hu L; Yang G; Dai B; Tao Y; Zhu W; Shi J
Theranostics; 2017; 7(15):3690-3699. PubMed ID: 29109769
[TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
5. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
6. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
[TBL] [Abstract][Full Text] [Related]
7. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
8. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
9. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.
Yao Y; Sun Y; Shi M; Xia D; Zhao K; Zeng L; Yao R; Zhang Y; Li Z; Niu M; Xu K
Oncotarget; 2016 Nov; 7(45):73497-73508. PubMed ID: 27634873
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
Kacı FN; Kiraz Y; Çekdemir D; Baran Y
Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
[TBL] [Abstract][Full Text] [Related]
12. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J; Cervi D; Ooi M; Kim K; Nahar S; Klippel S; Cholujova D; Leiba M; Daley JF; Delmore J; Negri J; Blotta S; McMillin DW; Hideshima T; Richardson PG; Sedlak J; Anderson KC; Mitsiades CS
Haematologica; 2011 Aug; 96(8):1170-9. PubMed ID: 21712538
[TBL] [Abstract][Full Text] [Related]
17. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
20. Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.
Vasuthasawat A; Yoo EM; Trinh KR; Lichtenstein A; Timmerman JM; Morrison SL
MAbs; 2016 Oct; 8(7):1386-1397. PubMed ID: 27362935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
